Back to results
US 10,246,500 B2Granted
Human cytolytic fusion proteins
AssigneeUniversity of Cape Town
InventorsStefan Barth, Thomas Nachreiner, Christian Cremer
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Cape Town
InventorsStefan Barth, Thomas Nachreiner, Christian Cremer
Estimating the term…
The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof; to nucleic acid molecules encoding said recombinant hCFPs, vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.
A recombinant human cytolytic fusion protein (hCFP) suitable to induce apoptosis in human target cells, comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64, and the effector domain comprises a variant or a functional fragment of wild type human angiogenin (Ang) as shown in SEQ ID NO:
A recombinant human cytolytic fusion protein (hCFP) suitable to induce apoptosis in human target cells, comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64, and the effector domain comprises a variant or a functional fragment of wild type human angiogenin (Ang) as shown in SEQ ID NO:
A recombinant human cytolytic fusion protein (hCFP) suitable to induce apoptosis in human target cells, comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64, and the effector domain comprises a variant or a functional fragment of wild type human angiogenin (Ang) as shown in SEQ ID NO:
Dependencies are inferred from the claim text.